Cantor Fitzgerald Forecasts Strong Price Appreciation for Elevance Health (NYSE:ELV) Stock

Elevance Health (NYSE:ELV) had its target price raised by analysts at Cantor Fitzgerald from $400.00 to $450.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target points to a potential upside of 10.20% from the company’s previous close.

Other equities analysts have also issued reports about the company. UBS Group boosted their price target on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Robert W. Baird increased their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Jefferies Financial Group dropped their price objective on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Leerink Partners set a $364.00 target price on shares of Elevance Health in a research note on Thursday, April 23rd. Finally, The Goldman Sachs Group raised their price target on shares of Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Fifteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $420.70.

Elevance Health Stock Down 2.3%

Shares of NYSE:ELV opened at $408.35 on Tuesday. The company has a market capitalization of $88.68 billion, a price-to-earnings ratio of 17.37, a PEG ratio of 2.37 and a beta of 0.67. Elevance Health has a 12-month low of $273.71 and a 12-month high of $427.19. The business has a 50-day moving average price of $391.29 and a 200 day moving average price of $351.07. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts expect that Elevance Health will post 26.86 EPS for the current year.

Insider Activity

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Elevance Health

A number of hedge funds and other institutional investors have recently bought and sold shares of ELV. Kemnay Advisory Services Inc. acquired a new stake in shares of Elevance Health during the 4th quarter worth approximately $31,000. J.Safra Asset Management Corp acquired a new stake in Elevance Health in the fourth quarter worth $32,000. WealthCollab LLC lifted its stake in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after buying an additional 27 shares during the last quarter. ORG Partners LLC lifted its stake in Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after buying an additional 59 shares during the last quarter. Finally, Dorato Capital Management acquired a new position in shares of Elevance Health during the fourth quarter valued at $41,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.